Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Scholar Rock Holding Corporation - Common Stock
(NQ:
SRRK
)
46.94
+1.44 (+3.16%)
Delayed Quote
Updated: 4:00 PM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Scholar Rock Holding Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Scholar Rock to Present at Upcoming Investor Conferences
November 03, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026
October 20, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 16, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
October 08, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock (NASDAQ:SRRK) Rallies 17% as Regulatory Catalysts Outweigh In-Line Q2 Results
↗
August 06, 2026
Via
Chartmill
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 21, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
September 11, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
September 02, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present at Upcoming Investor Conferences
August 27, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
August 21, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab
↗
August 17, 2026
Scholar Rock (NASDAQ:SRRK) CEO David Hallal said the company is preparing for a September 30 FDA decision date for apitegromab, its investigational treatment for spinal muscular atrophy, or SMA,...
Via
MarketBeat
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 14, 2026
From
Scholar Rock, Inc.
Via
Business Wire
Scholar Rock (SRRK) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
Apitegromab awaits FDA decision on Sept. 30 for spinal muscular atrophy treatment.
Via
The Motley Fool
Topics
Earnings
Economy
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
August 07, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock Q2 Earnings Call Highlights
↗
August 07, 2026
Scholar Rock (NASDAQ:SRRK) said its resubmitted biologics license application for apitegromab remains on track for a U.S. Food and Drug Administration decision by its Sept. 30 PDUFA date, as the...
Via
MarketBeat
Topics
Earnings
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 06, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference
July 29, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)
July 20, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
July 16, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD
June 22, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 12, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference
May 20, 2026
From
Scholar Rock, Inc.
Via
Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2026
From
Scholar Rock, Inc.
Via
Business Wire
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma
↗
May 14, 2026
Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.
Via
The Motley Fool
Topics
Regulatory Compliance
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO
↗
May 14, 2026
Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach.
Via
The Motley Fool
Topics
Initial Public Offering
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700%
↗
May 14, 2026
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types.
Via
The Motley Fool
Topics
Regulatory Compliance
Scholar Rock Q1 Earnings Call Highlights
↗
May 08, 2026
Scholar Rock (NASDAQ:SRRK) said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company’s investigational treatment for...
Via
MarketBeat
Topics
Earnings
Scholar Rock (SRRK) Q1 2026 Earnings Transcript
↗
May 08, 2026
Scholar Rock (SRRK) Q1 2026 Earnings Transcript
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
